The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines
The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines
The first phase of the programme will be in place in hospitals across the UK by March 2025
Affecting the immune system, various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns
Affecting more than 7 million people in the UK, cardiovascular diseases are conditions that affect the heart or circulation
The proposals will help MedTech developers access NHS funding to fast-track products
The project will validate two minimally invasive biomarkers for ALS: MMP-9 and TIMP-1
The MRC BRC and the MDU will use the funding and cutting-edge research to improve public health until March 2029
Impacting more than 150,000 people in the UK, the lifelong autoimmune disease affects the brain and spinal cord
The conference will take place on 23 to 24 October at Vienna AirportCity
JHU083 reduced tumour growth and triggered tumour cell death in mice
High-grade gliomas are rare, malignant tumours which account for up to 12% of all childhood brain tumours
The partnership will provide six MRC clinical fellows with industry placement opportunities
Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually
The nanocage technology combines both mRNA and traditional virus-based vaccines to create virus-like efficacious vaccines
The funding aims to reduce health inequalities in these groups and save more lives